Colorectal Cancer (Therapy)

Results of Irinotecan Reported on at Conference

Published in Cancer Weekly, November 13th, 1995

Rhone-Poulenc Rorer Inc. (RPR), Paris, France, announced that Campto (irinotecan), an innovative new anti-cancer agent, has demonstrated significant activity in the treatment of advanced colorectal cancer, according to research presented at the 8th Annual European Cancer Conference (ECCO-8).

"Phase II clinical trials conducted in Europe, the United States, and Japan confirm that Campto has significant activity in advanced colorectal cancer," said Dr. Jean-Pierre Armand, one of the principal clinical investigators of Campto at the Institute Gustave Roussy in France.

"There is a growing body of research that indicates Campto is effective both as a...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1995-11-13)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry